CAR-T therapies by BMS and Janssen reported successful

CAR-T therapies that are being developed by Bristol Myers Squibb and Janssen have all hit targets in early-mid-stage trials. Increasing hopes of new treatment options for difficult to treat blood cancers. Johnson & Johnson’s Janssen unveiled initial results from the Phase Ib/II CARTITUDE-1 study assessing the efficacy and safety of JNJ-68284528 (JNJ-4528) – an investigational B cell

Continue Reading

Pfizer and Astellas gain positive trial results for prostate cancer treatment

Pfizer and Astellas have announced results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Enzalutamide had significantly improved radiographic progression-free survival, paving the way for an application to expand the drug’s use. The results, which are for the drug in combination with androgen deprivation therapy, show a

Continue Reading

Celgene and Jounce in $2.6-bn Immuno-Oncology Collaboration Deal

Celgene and Jounce Therapeutics are to join in a global strategic collaboration with the aim of developing and commercialising immuno-oncology treatments. The collaboration will provide Celgene the options to jointly develop and commercialise Jounce’s primary product candidate, JTX-2011, and other innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.

Continue Reading

Nanomedicine Combinination Could Improve Outcomes for Pancreatic Cancer Patients

A report has stated that a nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumours whilst decreasing toxicity. In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine

Continue Reading